MET and non-small cell lung carcinoma: Therefore, our results suggested that miR‐1‐3p/miR‐206 is able to down‐regulate c‐Met and EGFR expression and inhibit downstream Akt and Erk pathways in HGF‐induced gefitinib‐resistant NSCLC cells.